JDP 2026 – The Epilogy Team at the Journées Dermatologiques de Paris
Oral communications and a CME session at the major French dermatology meeting
The Journées Dermatologiques de Paris (JDP), the major annual meeting of French dermatology, will take place from December 1 to 5, 2026, at the Palais des Congrès (Porte Maillot, Paris). They bring together dermatologists, researchers and healthcare professionals around the latest scientific and clinical advances.
Members of the Epilogy team will be present throughout the 2026 edition to deliver oral communications based in particular on French National Health Data System (SNDS) studies, and to take part in a continuing medical education (CME) session dedicated to the must-read systematic reviews of the year.
Find all the Epilogy team presentations below:
Wednesday, December 2
Infectious Dermatoses 14:15 – 15:45
Risk of serious infections with TNF inhibitors in patients with sarcoidosis: a nationwide exposed/unexposed cohort study using the French National Health Data System
Impact of biologic initiation on care pathways and antibiotic consumption in hidradenitis suppurativa: a nationwide cohort of 7,651 patients from the French National Health Data System (SNDS)
Risk of herpes zoster with targeted therapies for immune-mediated inflammatory diseases: a comparative nationwide cohort study
Severe lichenoid dermatoses induced by immune checkpoint inhibitors: impact on subsequent oncological management
Cutaneous Adverse Drug Reactions
Severe immune-related adverse events of anti-PD-1 therapy in the management of advanced cutaneous squamous cell carcinoma: a nationwide cohort study using the French National Health Insurance database (CEc-iTox study)
Thursday, December 3
Allergology Session 09:00 – 10:30
Comparison of tralokinumab and JAK inhibitor persistence after dupilumab failure in atopic dermatitis: a nationwide cohort (DATOP project)
Continuing Medical Education (CME) 16:15 – 17:45
10 must-read systematic reviews of 2026 for my practice
Friday, December 4
Paediatric Dermatology – Genetics
Life expectancy and risk of death in patients with neurofibromatosis type 1: a cohort study from 1980 to 2025
Incidence and prognosis of complications of neurofibromatosis type 1: a study of 22,157 patients from the French National Health Data System
Bullous Dermatoses